Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 5, 2008, Pages 589-597

  Yamamoto, S ^a   Nakase, H ^a   Mikami, S ^a   Inoue, S ^a   Yoshino, T ^a   Takeda, Y ^a   Kasahara, K ^a   Ueno, S ^a   Uza, N ^a   Kitamura, H ^a   Tamaki, H ^a   Matsuura, M ^a   Inui, K ^a   Chiba, T ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; MESALAZINE; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; COLON RESECTION; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; GINGIVITIS; HEADACHE; HOT FLUSH; HUMAN; HYPERKALEMIA; HYPOMAGNESEMIA; JAPAN; KIDNEY DYSFUNCTION; MALE; MODIFIED TRUELOVE WITTS SEVERITY INDEX; MORTALITY; NAUSEA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; MALE; MIDDLE AGED; REMISSION INDUCTION; TACROLIMUS; TREATMENT OUTCOME;

EID: 48449086177     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03764.x     Document Type: Article

References (36)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 347 : 417 29.
2. Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion 2006 73 (Suppl. 1 67 76.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007 369 : 1641 57.
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330 : 1841 5.
5. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short term and long term responses. Dig Dis Sci 1996 41 : 2471 6.
6. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998 12 : 973 8.
7. Van Gossum A, Schmit A, Adler M, et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Belgian IBD Group. Acta Gastroenterol Belg 1997 60 : 197 200.
8. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999 94 : 1587 92.
9. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis. Eur J Gastroenterol Hepatol 1998 10 : 411 5.
10. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005 1 : CD004277.
11. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005 22 : 907 16.
12. Garcia S, Gisbert JP, Gomollon F. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005 28 : 607 14.
13. Weber A, Fein F, Koch S, et al. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (Neoral). Inflamm Bowel Dis 2006 12 : 1131 5.
14. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000 80 : 1483 521.
15. Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta 2001 313 : 241 53.
16. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987 40 : 1256 65.
17. Fujisawa Healthcare Inc. Prograf (Tacrolimus) full prescribing information. Physician's Desk Reference. Montvale, NJ : Thomson, 2005 : 1098 102.
18. Haddad EM, McAlister VC, Renouf E, et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006 18 : CD005161.
19. Webster A, Taylor RS, Chapman JR, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005 19 : CD003961.
20. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998 9 : 2303 14.
21. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000 96 : 2062 8.
22. Ogata H, Matsui T, Nakamura M, et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006 55 : 1255 62.
23. Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid- refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 2006 101 : 1048 56.
24. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002 8 : 317 24.
25. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007 13 : 129 34.
26. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990 336 : 16 9.
27. Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007 45 : 306 11.
28. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003 18 : 415 23.
29. Langnas AN. Advances in small-intestine transplantation. Transplantation 2004 15 : S75 8.
30. McMaster P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995 17 : 602 5.
31. Lopez-Sanroman A, Bermejo F, Carrera E, et al. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004 20 : 161 6.
32. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002 50 : 485 9.
33. Steinhart AH, Baker JP, Brzezinski A, et al. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 1990 12 : 271 5.
34. Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996 91 : 2498 9.
35. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 76.
36. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008 22 : 1 15.